Tredje Ap Fonden Alnylam Pharmaceuticals, Inc. Transaction History

Tredje Ap Fonden

$10.8 Billion
Q3 2024

A detailed history of Tredje Ap Fonden transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Tredje Ap Fonden holds 19,483 shares of ALNY stock, worth $4.94 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

19,483

Previous 19,483 -0.0%

Holding current value

$4.94 Million

Previous $4.73 Million 13.2%

% of portfolio

0.05%

Previous 0.05%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$143.31 - $247.0 $44,139 - $76,076	-308 Reduced 1.56%	19,483 $4.73 Million
Q4 2023 Feb 12, 2024	SELL	$151.41 - $196.57 $115,828 - $150,376	-765 Reduced 3.72%	19,791 $3.79 Million
Q3 2023 Nov 09, 2023	SELL	$170.77 - $211.65 $309,435 - $383,509	-1,812 Reduced 8.1%	20,556 $3.64 Million
Q2 2023 Aug 11, 2023	SELL	$185.01 - $212.05 $688,237 - $788,826	-3,720 Reduced 14.26%	22,368 $4.25 Million
Q1 2023 May 10, 2023	BUY	$182.66 - $235.53 $333,171 - $429,606	1,824 Added 7.52%	26,088 $5.23 Million
Q4 2022 Feb 10, 2023	BUY	$185.53 - $241.31 $78,293 - $101,832	422 Added 1.77%	24,264 $5.77 Million
Q3 2022 Nov 10, 2022	BUY	$138.54 - $232.0 $3.3 Million - $5.53 Million	23,842 New	23,842 $4.77 Million
Q2 2018 Aug 09, 2018	SELL	$88.31 - $107.8 $635,832 - $776,160	-7,200 Closed	0 $0
Q1 2018 May 09, 2018	BUY	$115.92 - $148.54 $411,516 - $527,317	3,550 Added 97.26%	7,200 $858,000
Q4 2017 Feb 12, 2018	BUY	$114.49 - $139.98 $417,888 - $510,926	3,650	3,650 $464,000

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.2B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Tredje Ap Fonden, based on Form 13F filings with the SEC.

News

Stay updated on Tredje Ap Fonden with notifications on news.

Account